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Abstract

Nicotine can stimulate both sympathetic and parasympathetic ganglionic cells depending
on which ganglionic cells of the ANS it is able to access. This study involved the transdermal
delivery of low doses of nicotine and nitroglycerin to the forehead and finger microvasculature so
as to test the hypothesis that, although both drugs will cause vasodilation at the forehead, the
nature of the dilation will differ as a consequence of their different sites of action within the
neuro-microvascular pathways. With IRB approval, the local effects of transdermal nitroglycerin
and nicotine were investigated on the forehead and finger of 10 healthy volunteers resting supine
in a temperature-regulated room (22±1°C). Each micropatch was placed on the forehead and
finger beneath a laser Doppler flowmetry (LDF) probe which measured the relative blood flow.
The changes in the height (AC) and the baseline (DC) components of the laser Doppler signal
were assessed as well as the power of the signal at different frequencies. Both drugs caused
significant vasodilation at the forehead vasculature. The increase in the AC component was larger
for nicotine than for nitroglycerin. Similarly the DC component showed a larger increase for
nicotine than for nitroglycerin. There was no significant increase in either component at the
finger. The FFT analysis showed marked oscillatory activity at the nicotine application site for
virtually every frequency that we studied up to about 0.3. Both nicotine and nitroglycerin caused
vasodilation of the forehead microvasculature while not at the finger. Nicotine may turn out to be
the ideal transdermal preparation for testing a disorder such as diabetic neuropathy and the impact
of diabetes on endothelium-dependent vasodilation. Since intact postganglionic parasympathetic
fibers are required for nicotine to exert its vasodilatory effect on the microvasculature, application
of a nicotine micropatch not only would test the vessel but also the post-ganglionic pathway and,
hence, potentially identify the autonomic neuropathic component.
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INTRODUCTION

NICOTINE
Nicotine is a drug consumed by millions of people worldwide. It is the main
compound responsible for addiction to tobacco. Nicotine replacement therapy in the form
of gum, transdermal patches, inhalers and nasal sprays is also widely used and is a
strategy employed for smoking cessation. It is a very intriguing drug from a physiologic
standpoint. The majority of data related to nicotine is focused on the systemic effects of a
relatively large dose of nicotine administered intravenously or locally and on its role as a
smoking cessation tool.
The effects of transdermal nicotine on the local microvasculature are not well
studied. However, as technology has improved, tools such as laser doppler flowmetry
(LDF) have emerged for measuring local blood flow. In this study, we investigated the
effects of transdermal nicotine on the skin microvasculature at different sites. We then
compared this response to nitroglycerin (a known vasodilator) in order to assess whether
there were differences in the response given the different mechanisms of action for each
drug.
It is well established that nicotine can stimulate sympathetic ganglionic cells in
low and moderate concentrations and thereby causes vasoconstriction and increased heart
rate among other effects [1]. It can also paralyze these cells at high doses. Less
appreciated is the fact that nicotine can also stimulate parasympathetic ganglionic cells
and also block them at high doses. Hence, the effects of nicotine at a given site is
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dependent on which ganglionic cells it is able to gain access to and which branch of the
autonomic nervous system is dominant in that region.
As previously mentioned, nicotine (NIC) is a neurotransmitter that can activate
both sympathetic and parasympathetic pathways. It is released by pre-ganglionic neurons
of both systems resulting in the release of norepinephrine (by postganglionic sympathetic
fibers) and acetylcholine (by postganglionic parasympathetic fibers).
Acetylcholine (ACh) is a known vasodilator. It is an endothelium dependent
vasodilator [2] which means that it requires intact endothelial cells to produce
vasodilation. This is because ACh, acting on ACh receptors on these cells, stimulates
release of the substances that cause vasodilation of the smooth muscle cells. Using
invasive measurements, it has been shown that the vasodilatory effect of acetylcholine is
impaired in patients with coronary artery disease [3]. Since ACh requires intact
endothelial cells in to function, ACh can be used to assess endothelial function.
A previous study by Schonberger et al [4] has used LDF to compare the response
of a prepared ACh transdermal patch with commercially available nitroglycerin
transdemal patch. They found an increase in blood flow in response to the application of
these patches. They were limited in that there is no commercially available acetylcholine
patch and hence had to produce their own. However, this was the first study of its kind
using LDF in conjunction with a translucent drug patch to measure changes in blood
flow. Since no ACh patch is available, transdermal nicotine is a good alternative in that it
stimulates ACh release via the mechanisms described above. Moreover, a commercially
available transdermal nicotine patch is already available.
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Using these patches with different mechanisms of action may provide insight into
the mechanism of blood flow regulation in tissues rich in cholinergic innervations (e.g.
centrally located regions) but not in tissues where such innervation is sparse or lacking
(e.g., more peripheral regions).
Systemic nicotine affects the cardiovascular system and typically leads to direct
and indirect increases in heart rate, blood pressure and also causes vasoconstriction. This
is due to its sympathomimetic effects as it stimulates the release of catecholamines. These
increases in heart rate and blood pressure increase myocardial work and oxygen demand.
Moreover, coronary vasoconstriction can lead to a decrease in blood flow to the heart.
These effects of nicotine can lead to significant morbidity and mortality especially in
individuals with underlying coronary artery disease. Given its mechanism of action,
application of transdermal nicotine to the forehead activates parasympathetic pathways
and thereby causes vasodilation of the local microvasculature. This may provide insight
into the mechanism of blood flow regulation in tissues rich in cholinergic innervations
(e.g., centrally located regions) but not in tissues where such innervation is sparse or
lacking (e.g., more peripheral regions).
When administered systemically, nicotine can gain access to pre-/post- ganglionic
junctions of both divisions of the autonomic nervous system. However, if given in a
small dose via the transdermal route, it should have no effect on the sympathetic
junctions since the synapse occurs in the paraverterbral sympathetic chain. Alternatively,
it may have an effect on parasympathetic junctions: in tissues which are innervated by the
parasympathetic nervous system, the pre/post synapse occurs near the end organ (e.g.,
within the vessel walls).
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Transdermal nicotine patches deliver on average between 15-22mg of nicotine per
day depending on the type of patch used and whether it is used during sleep. [1] The
nicotine is slowly absorbed and blood plasma levels rise gradually over the course of 610 hours, then stay at steady state for 7-8 hrs eventually declining during the last 6 hours.
The amount absorbed into the blood stream varies by individual and is determined by
several factors including nicotine clearance, cutaneous blood flow, skin temperature etc.
The half life of nicotine is about 2-3 hours and it is metabolized by the liver, and to a
lesser extent in the lung and brain. Studies have shown the 21mg transdermal nicotine is
safe [5]. In this study, transdermal nicotine patches were left in place for 30 minutes
minimizing systemic effects substantially. In addition, the patches used were markedly
smaller than the original patch and only measured about 2cm X1cm.

NITROGLYCERIN
Nitroglycerin is a drug used to relieve the symptoms of angina. It has generally
been assumed that nitroglycerin relieves symptoms via the release of nitric oxide (NO),
which relaxes vascular smooth muscle cells. This occurs independently of acetylcholine
and other means of releasing NO (since the NO is supplied by the nitroglycerin).
In light of the different mechanisms of action of nicotine and nitroglycerin, we set
out to measure and quantify the response to local transdermal doses of nicotine and
nitroglycerin in different body regions. This will be accomplished by measuring the
blood flow directly using laser Doppler flowmetry. We will further be able to measure
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the autonomic response by measuring the frequencies of the response. This is due to the
fact that the sympathetic and parasympathetic systems oscillate at different frequencies.

LASER DOPPLER FLOWMETRY
Laser doppler flowmetry (LDF) is a non invasive method that has many practical
applications which include the measurement of microvascular blood flow. This allows us
to monitor blood flow changes to the tissue and thus can be a useful tool to assess the
effects of drugs on the tissue. While LDF does not provide absolute values, it gives us a
means of measuring relative changes. Hence, once a baseline flow is established, relative
increases or decreases in flow can be determined and quantified.

Measuring skin

perfusion has many clinical applications as many diseases can affect the skin such as
diabetic microangiopathy, Raynaud’s phenomenon, peripheral vascular disease leading to
various complications such as ulcers, neuropathies etc. In addition, it has clinical
applications in plastic surgery especially in flap surveillance, burns and pharmacology.
Hence, as a clinical tool, LDF allows the monitoring of skin blood perfusion in
real time, continuously and non invasively. The theory behind LDF, as its name implies,
is based on the Doppler effect which was described by Johan Christian Doppler . LDF are
designed using a fiber optic probe which is about 0.25mm between the transmitting and
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receiving fibers allowing for a sampling depth of approximately 1mm for human skin.
Coherent light directed towards the tissue causes photons to be scattered by both moving
and static objects. In the case of a moving object, the doppler effect occurs causing a
change in photon frequency. The reemitted light is then directed towards a photodetector
in which the combination of the shifted and non shifted light frequencies give rise to a
stochastic photocurrent. The properties of this photocurrent is related to the properties of
the blood cells present in the illuminated volume as they move at their different
velocities. Light can be viewed as a particle with some wave characteristics. The doppler
effect results in the scattering of light due to its interactions with the red blood cells.
These red blood cells are moving at very low velocities (mm/s) and hence give
rise to extremely small frequency shifts, much smaller than that of the incident light.
Several mathematical equations and models are thus used to give an estimate of the blood
flow. Several models have been proposed using complex mathematical equations. In
other for these models to work, certain assumptions need to be made. These assumptions
may not be fully true in biologic tissue but give us a good framework in which to make
these calculations. A few of these assumptions are outlined by Humeau et al [1] and are
as follows :
1. Light suffers multiple scattering in the static tissue matrix, hence becoming
diffusely scattered.
2. The fraction of photons undergoing multiple doppler shifts is negligible.
3. The blood cell velocities are randomly distributed in direction within the
scattering volume, meaning that the network of microvessels, in effect, is
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random on a length scale defined by the mean distance between RBC
scattering events.
4. The statistics of the blood cell velocity field is uniform throughout the
scattering volume.
In summary, LDF measurements have evolved from the intial reports by Riva et
al in 1972, who reported that microvasculature blood flow measurements could be
measured with the Doppler effect. Several studies have been carried out to improve the
technique and measurements and the theory has now been established. LDF will only
continue to grow as a tool for measuring tissue perfusion, a very important indicator of
tissue health.
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STATEMENT OF PURPOSE

To measure the response of the forehead and finger microvasculature to transdermal
nicotine and transdermal nitroglycerin using laser doppler flowmetry on healthy
volunteers. Since these drugs work by different mechanisms, this can be used as a novel
non invasive way to assess the function of the microvasculature as we can compare the
changes to disease states.
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METHODS
The study was carried out on 10 healthy non-smoking volunteers between the
ages of 20 and 26 who were instructed to refrain from caffeine for at least twenty four
hours. After informed consent was obtained, the subjects lay on a bed in a semirecumbent position in a temperature controlled room (22+1C) and were monitored using
an ECG and non-invasive brachial artery blood pressure cuff. A baseline blood pressure
and pulse were obtained at the beginning of the experiment in other to monitor any
systemic changes.
A 6-mm diameter circle was obtained from the two patches: a clear nitroglycerin
patch (Minitran, 3M Pharmaceuticals, Northridge, CA) and transdermal nicotine
(Nicoderm CQ, GlaxoSmithKline). Each subject received both the nicotine and
nitroglycerin patch in separate sessions. The order was randomly determined.
Each micropatch (i.e the nicotine or nitroglycerin patch) was placed on the
forehead beneath a laser Doppler flowmetry (LDF) probe (PF5010, Perimed), a second
LDF probe was placed on the finger, while the third LDF probe served as the control for
the forehead. There was no finger control since there were only three probes available.
LDF readings were recorded continuously at 200 Hz for 20 minutes, with a data
acquisition system (PowerLab, ADInstruments) and analyzed with commercially
available software (Chart, ADInstruments). This procedure was repeated for both sets of
patches.
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The changes in the height (AC) and the baseline (DC) components of the laser
Doppler signal were assessed for each drug and compared with placebo using a paired t
test.
Microvascular oscillatory patterns were delineated with spectral analysis for each LDF
tracing using a 32K FFT size and a Hamming window. Three different frequency ranges
(0.05-0.11, 0.12-0.19 and 0.2-0.3 were selected and analyzed for each site. The basis for
these three bands is addressed below. The low frequency bands (0.05- 0.11Hz) represent
oscillations in the microvasculature due to sympathetic activity. These sympatheticinduced oscillations are limited to low frequencies (<9 cycles/s) [6]. The oscillations
occurring at higher frequency bands ( > 9 cycles/s) represent parasympathetic mediated
activity. The cholinergic etiology of these HF oscillations was confirmed by their
elimination by systemic administration of atropine. [7]. The higher frequency band (0.120.3 Hz) was divided into an intermediate frequency band (0.12-0.19Hz) and a high
frequency band (0.2-0.3Hz).

This is in order to distinguish between oscillations

transmitted to microvasculature due to respiration (which typically has a frequency of
~0.2Hz) or a cholinergic mediated process occurring at the level of the
microvasculature.[6]

The presence of systemic effects was monitored at the control site, as well as by
measurements of heart rate and blood pressure.
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RESULTS
TIME DOMAIN RESULTS

Figure 1a- Nicotine Laser Doppler Tracings showing forehead, placebo and finger
as drug from patch is absorbed over time.

Figure 1a shows a tracing from a single subject. Channel 1 (uppermost channel) shows
the LDF tracing for nicotine at the forehead. Channel 2 (middle channel) shows the
placebo at the forehead. Channel 3 (bottom channel) shows the tracing for nicotine at the
finger site. The forehead tracing shows an upward change as time progresses. The
placebo tracing remains unchanged while the finger tracing shows large fluctuations but
does not seem to increase.
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Figure 1b- Nicotine Laser Doppler Tracings magnified

Figure 1b above shows a magnified portion of the Figure 1a. This illustrates that the
tracing is composed of individual oscillating waveforms. The forehead tracing shows an
increase in the LDF signal accompanied by an increase in the height of the individual
waveforms. The placebo tracing shows no increase in LDF signal value and the
individual waveforms remain unchanged. The finger tracing shows a minimal increase in
LDF signal along with large fluctuations in the signal.
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Figure 2a- Nitroglycerin Laser Doppler Tracings of forehead, placebo and finger in response to
drug from patch being absorbed over time.

Figure 2a shows a tracing from a single subject. Channel 1 (uppermost channel) shows the LDF
tracing for nitroglycerin at the forehead. Channel 2 (middle channel) shows the placebo at the
forehead. Channel 3 (bottom channel) shows the tracing for nitroglycerin at the finger site. The
forehead tracing shows an upward change as time progresses. The placebo tracing remains
unchanged while the finger tracing shows an increase.
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Figure 2b- Nitroglycerin Laser Doppler Tracings Magnified

Figure 2b above shows a magnified portion of the Figure 2a. This illustrates that the tracing is
also composed of oscillations which change over time as nitroglycerin is absorbed.

The

forehead tracing shows an increase in the LDF signal accompanied by an increase in the
individual waveforms. The placebo tracing shows no change in LDF value and the individual
waveforms remain unchanged. The finger tracing shows a very minimal increase in the LDF
signal.

15

TABLE 1- FOREHEAD NICOTINE BASELINE VALUES
FOREHEAD
NICOTINE
PLACEBO
SUBJECT BaselinePRE
1
0.2048
2
0.1108
3
0.1106
4
0.05285
5
0.5156
6
0.13355
7
0.067565
8
0.01739
9
0.048315
10
0.0375

FOREHEAD
NICOTINE
PLACEBO
BASELINE POST
0.157
0.09523
0.1007
0.079915
0.6549
0.1103
0.067315
0.02531
0.04924
0.037735

FOREHEAD
NICOTINE
BASELINE PRE
0.1625
0.06363
0.07804
0.1124
0.062565
0.04961
0.07411
0.02633
0.04824
0.0692

FOREHEAD
NICOTINE
BASELINE POST
0.4727
0.3985
0.4955
0.369
0.1807
0.1921
0.1115
0.03677
0.13385
0.361

MEAN
0.129897
0.1377645
0.0746625
0.275162
SD
0.146363266
0.185752101
0.038167714
0.162741626
median 0.0890825
0.0875725
0.066415
0.27655
min
0.01739
0.02531
0.02633
0.03677
max
0.5156
0.6549
0.1625
0.4955
*BaselinePRE – defined as the trough of the waveform before drug administered
* BaselinePOST- trough value after drug administered.

TABLE 2- T TEST PROCEDURE NICOTINE FOREHEAD BASELINE
Difference = FOREHEAD NICOTINE BASELINERATIO – FOREHEAD NICOTINE BASELINE
RATIO
N
MEAN
STD DEV
STD ERR
MIN
MAX
10
2.5835
1.9069
0.6030
-.0589
5.4388
DF
9

T value
4.28

Pr> |t|
0.002
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Table 1 above compares the changes in Forehead Baseline values pre and post drug
administration for nicotine compared to placebo. Baseline is defined as the trough of the
waveform. At the forehead, transdermal nicotine patch resulted in a significant increase in the
baseline value with an increase in the mean from 0.07 to 0.27 while the mean remained
unchanged for placebo. The t test in table 2 showed these results to be statistically significant
with a p value of 0.002.

TABLE 3- NICOTINE FOREHEAD HEIGHT VALUES
FOREHEAD
SUBJECT PLACEBO
HEIGHT PRE
1
0.01495
2
0.05835
3
0.057995
4
0.013885
5
0.1237
6
0.06601
7
0.018085
8
0.015715
9
0.01996
10
0.007589

FOREHEAD
PLACEBO
HEIGHT POST
0.021715
0.05038
0.05079
0.02759
0.1601
0.06124
0.01561
0.003125
0.02012
0.0048435

FOREHEAD
NICOTINE
HEIGHT PRE
0.03086
0.02308
0.028125
0.02661
0.050205
0.022295
0.0205
0.015305
0.02063
0.01952

FOREHEAD
NICOTINE
HEIGHT POST
0.1535
0.1686
0.14465
0.05571
0.1053
0.06311
0.03399
0.01565
0.05092
0.099155

MEAN
SD
median
min
max

0.04155135
0.046127155
0.0246525
0.003125
0.1601

0.025713
0.009725564
0.0226875
0.015305
0.050205

0.0890585
0.053330247
0.0811325
0.01565
0.1686

0.0396239
0.036777011
0.0190225
0.007589
0.1237
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TABLE 4- T TEST PROCEDURE NICOTINE FORHEHEAD HEIGHT
Difference = FOREHEAD NICOTINE BASELINERATIO – FOREHEAD NICOTINE BASELINE
RATIO
N
MEAN
STD DEV
STD ERR
MIN
MAX
10
2.45
2.0974
0.6601
0.1065
6.44
DF
9

T value
3.72

Pr> |t|
0.0048

Table 3 above compares the changes in Forehead Height values pre and post drug
administration for nicotine compared to placebo. Height is defined as the peak of the
waveform. At the forehead, transdermal nicotine patch resulted in a significant increase
in the Height value with an increase in the mean from 0.03 to 0.09 while placebo remained
unchanged from 0.039 to 0.041. The t test in table 4 showed that these results to be

statistically significant (See Table 2) with a p value of 0.0048.
At the forehead, both baseline and height approximately tripled in response to
transdermal nicotine with baseline increasing approx 3.85 times compared to height
increasing approx 3 times.
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Table 5- Forehead Nitroglycerin Baseline Values
SUBJECT FOREHEAD
NITRO PLACEBO
BaselinePRE
0.1357
1
0.048345
2
0.08125
3
0.09746
4
0.12545
5
0.1187
6
0.10465
7
0.1031
8
0.05557
9
0.07906
10
MEAN
SD
median
min
max

0.0949285
0.028838006
0.10028
0.048345
0.1357

FOREHEAD
NITRO PLACEBO
Baseline POST
0.2367
0.051735
0.08458
0.1045
0.11535
0.1636
0.09281
0.13
0.07837
0.073775

FOREHEAD NITRO
BaselinePRE
0.1094
0.083635
0.09732
0.09796
0.041265
0.06358
0.05311
0.1216
0.05513
0.092545

FOREHEAD NITRO
BaselinePOST
0.2987
0.1529
0.2102
0.2799
0.08307
0.1134
0.1029
0.2981
0.15685
0.1675

0.113142
0.053681355
0.098655
0.051735
0.2367

0.0815545
0.026823487
0.08809
0.041265
0.1216

0.186352
0.081464272
0.162175
0.08307
0.2987

TABLE 6- T TEST PROCEDURE NITROGLYCERIN FORHEHEAD BASELINE
Difference = FOREHEAD NITRO BASELINERATIO – FOREHEAD NITRO BASELINE RATIO
N
MEAN
STD DEV
STD ERR
MIN
MAX
10
1.0700
0.3720
0.1176
0.4053
1.7851
DF
9

T value
9.09

Pr> |t|
<0.0001
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Table 5 above compares the changes in Forehead Baseline values pre and post drug
administration for nitroglycerin compared to placebo. Baseline is defined as the trough of the
waveform. As shown above, transdermal nitro patch resulted in a significant increase in the
baseline value with an increase in the mean from 0.081 to 0.18 while the mean remained
unchanged for placebo. The t test in table 6 showed these results to be statistically significant
with a p value < 0.0001.

TABLE 7- FOREHEAD NITROGLYCERIN HEIGHT VALUES
FOREHEAD NITRO FOREHEAD NITRO
FOREHEAD NITRO
SUBJECT PLACEBO HEIGHT PLACEBO HEIGHT
HEIGHT PRE
PRE
POST
1
0.03206
0.03869
0.02466
2
0.004375
0.005625
0.02092
3
0.046715
0.047415
0.04184
4
0.07562
0.07338
0.0298
5
0.03993
0.038935
0.017125
6
0.04471
0.03073
0.02597
7
0.0274
0.0226
0.020515
8
0.0075
0.004063
0.024745
9
0.023555
0.01672
0.01655
10
0.38325
0.44855
0.02585

FOREHEAD
NITRO HEIGHT
POST
0.05583
0.04572
0.08282
0.051145
0.02869
0.04026
0.02514
0.06122
0.0553
0.046125

MEAN
SD
median
min
max

0.049225
0.016535355
0.048635
0.02514
0.08282

0.0685115
0.112469849
0.035995
0.004375
0.38325

0.0726708
0.13367253
0.03471
0.004063
0.44855

0.0247975
0.007289561
0.0247025
0.01655
0.04184
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TABLE 8- T TEST PROCEDURE NITROGLYCERIN FORHEHEAD HEIGHT
Difference = FOREHEAD NITRO HEIGHT RATIO – FOREHEAD NITRO HEIGHT RATIO
N
MEAN
STD DEV
STD ERR
MIN
MAX
10
1.0809
0.6800
0.2150
0.4006
2.6316
DF
9

T value
5.03

Pr> |t|
0.0007

Table 7 above compares the changes in Height values pre and post drug administration
for nitroglycerin compared to placebo. Height is defined as the peak of the waveform.
As shown above, transdermal nicotine patch resulted in a significant increase in the
Height value with an increase in the mean from 0.024 to 0.049. The t test in table 8
showed that these results to be statistically significant (See Table 2) with a p value of
0.0007.

SUBJECT

TABLE 9- FINGER BASELINE NICOTINE VS NITROGLYCERIN
FINGER NICOTINE FINGER NICOTINE FINGER
NITRO FINGER
NITRO
BASELINE PRE
BASELINE POST
BASELINE PRE
BASELINE POST

1
2
3
4
5
6
7
8
9
10

2.229
0.4115
0.5828
0.55305
0.7278
1.375
1.461
0.01541
0.4083
0.3719

1.4035
0.6481
0.5911
0.7157
0.7576
1.302
1.846
1.5025
0.50215
0.6518

0.3017
0.1053
1.8585
0.6933
1.916
0.225
0.7785
0.11305
0.9962
1.353

0.3323
0.1975
2.931
1.4985
1.8095
0.3595
1.391
0.8521
0.84865
1.7375

MEAN
SD
median
min
max

0.813576
0.66869102
0.567925
0.01541
2.229

0.992045
0.473910518
0.73665
0.50215
1.846

0.834055
0.686688323
0.7359
0.1053
1.916

1.195755
0.849247482
1.12155
0.1975
2.931
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TABLE 10- T TEST FINGER NITROGLYCERIN VS NICOTINE BASELINE
Difference = FINGER NICOTINE BASELINE RATIO – FINGER NITROGLYCERIN
BASELINE RATIO
N
MEAN
STD DEV STD ERR MIN
MAX
10
-0.18
0.5483
0.1734
-1.0642
0.7480
DF
9

T value
-1.06

Pr> |t|
0.3181

At the finger, neither transdermal nicotine or nitroglycerin produced a statistically
significant increase in the mean baseline value (Table 9). However, for nitroglycerin, all
but 2 subjects showed an increase in baseline values. The t test (table 10) showed that
there was no difference between nicotine and nitroglycerin at the finger.

TABLE 11- FINGER HEIGHT NICOTINE VS NITROGLYCERIN
FINGER
FINGER
FINGER NITRO
FINGER NITRO
SUBJECT NICOTINE
NICOTINE
HEIGHT PRE
HEIGHT POST
HEIGHT PRE
HEIGHT POST
1
0.4114
0.4029
0.15
0.1076
2
0.08622
0.09903
0.05793
0.1014
3
0.05805
0.06543
0.08577
0.11755
4
0.09755
0.1032
0.086535
0.18525
5
0.035665
0.02949
0.1441
0.2847
6
0.3898
0.4143
0.06231
0.1082
7
0.4243
0.4425
0.2642
0.2734
8
0.015825
0.3066
0.018315
0.3276
9
0.07122
0.2133
0.2469
0.21495
10
0.06453
0.09367
0.38325
0.44855
MEAN
SD
median
min
max

0.165456
0.169491441
0.07872
0.015825
0.4243

0.217042
0.160758375
0.15825
0.02949
0.4425

0.149931
0.114761702
0.1153175
0.018315
0.38325

0.21692
0.116277291
0.2001
0.1014
0.44855

22
TABLE 12- T TEST FINGER NITROGLYCERIN VS NICOTINE HEIGHT
Difference = FINGER NIC HEIGHT RATIO – FINGER NITRO HEIGHT RATIO
N
MEAN
STD DEV
STD ERR
MIN
MAX
10
0.0413
1.0658
0.3370
-1.1489
2.1243
DF
9

T value
0.12

Pr> |t|
0.9053

At the finger, neither transdermal nicotine or nitroglycerin produced a statistically
significant increase in the mean height value (Table 11). However, for nitroglycerin, all
but 1 subject showed an increase in height values. The t test (table 12) showed that there
was no difference between nicotine and nitroglycerin at the finger.
FREQUENCY DATA

SUBJECT

1
2
3
4

FOREHEAD
NICOTINE
LOW FREQ
BAND PRE
5.63166E-06
3.72965E-06
4.45215E-06
3.65387E-06

TABLE 13- FOREHEAD NICOTINE FREQUENCY BANDS
FOREHEAD
FOREHEAD
FOREHEAD NICOTINE
NICOTINE
FOREHEAD
NICOTINE
INTERMEDIATE INTERMEDIATE NICOTINE
LOW FREQ
FREQ BAND
FREQ BAND
HIGH FREQ
BAND POST PRE
POST
BAND PRE
0.000110025 2.49636E-07
2.97973E-05
3.35998E-06
3.53911E-05
2.0305E-06
1.70647E-05
3.0235E-06
0.000174027 3.38021E-06
1.70575E-05
4.68164E-06
2.30778E-05
1.27075E-06
7.47765E-06
4.60988E-07

FOREHEAD
NICOTINE
HIGH FREQ
BAND POST
1.7396E-05
2.82662E-05
1.27978E-05
3.95348E-06

5
6
7
8
9
10

1.7489E-06

3.20392E-06

1.96322E-06

1.35523E-06

7.83363E-07

2.13073E-06

1.58617E-05
8.1573E-06
7.65652E-07
6.81623E-06
7.0996E-06

0.000104949
5.85464E-06
2.78587E-06
2.64045E-05
1.6749E-05

6.3265E-06
2.26862E-05
1.01985E-06
3.52142E-06
1.29325E-06

4.65265E-05
8.25939E-06
1.03477E-06
7.21656E-06
6.79217E-06

1.85889E-06
2.96968E-06
3.96838E-07
1.36121E-06
1.21396E-06

2.96587E-05
1.10726E-06
8.78938E-07
6.61361E-06
3.85717E-06

MEAN
SD
median
min
max

5.79167E-06
4.24275E-06
5.04191E-06
7.65652E-07
1.58617E-05

5.02467E-05
5.86637E-05
2.47412E-05
2.78587E-06
0.000174027

4.37416E-06
6.66292E-06
1.99686E-06
2.49636E-07
2.26862E-05

1.42582E-05
1.4248E-05
7.86852E-06
1.03477E-06
4.65265E-05

2.01101E-06
1.43341E-06
1.61005E-06
3.96838E-07
4.68164E-06

1.0666E-05
1.09958E-05
5.28355E-06
8.78938E-07
2.96587E-05
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TABLE 14- FOREHEAD NITROGLYCERIN FREQUENCY BANDS

SUBJECT

FOREHEAD
NITRO
LOW FREQ
BAND PRE

FOREHEAD
NITRO
LOW FREQ
BAND POST

FOREHEAD
NITRO
INTERMEDIATE
FREQ BAND
PRE

FOREHEAD
NITRO
INTERMEDIATE
FREQ BAND
POST

FOREHEA
D NITRO
HIGH
FREQ
BAND PRE

FOREHEAD
NITRO HIGH
FREQ BAND
POST

1

1.47979E-05

2.55146E-05

1.87651E-06

3.02624E-05

1.45156E-06

3.78071E-06

2

4.33692E-06

8.86632E-06

5.15565E-06

1.70664E-05

6.46802E-06

9.27677E-06

3

3.98981E-06

1.58643E-05

4.49222E-06

5.09366E-06

3.16375E-06

4.62797E-06

4

1.04493E-05

1.74053E-05

2.01758E-05

4.04614E-05

2.84992E-06

4.89007E-06

5

1.199E-05

2.33307E-05

6.69577E-06

1.44572E-05

9.30115E-06

8.34185E-06

6

4.02893E-06

2.38241E-06

6.50801E-07

1.68911E-06

4.50839E-07

5.93199E-07

7

1.19847E-05

1.80827E-06

1.48299E-05

1.41082E-05

3.29327E-06

4.1182E-06

8

4.35106E-06

1.89279E-06

6.91813E-07

7.08439E-06

3.05284E-07

6.54937E-07

9

2.79192E-06

6.94711E-06

1.12438E-05

4.3055E-05

1.03984E-06

7.04108E-06

10

1.55688E-06

5.32697E-06

9.4687E-07

1.69044E-06

1.19139E-06

1.85762E-06

MEAN

7.02774E-06

1.09339E-05

6.67591E-06

1.74968E-05

2.9515E-06

4.51824E-06

SD

4.73495E-06

8.95804E-06

6.70528E-06

1.53711E-05

2.88895E-06

3.01648E-06

median

4.34399E-06

7.90671E-06

4.82393E-06

1.42827E-05

2.15074E-06

4.37309E-06

min

1.55688E-06

1.80827E-06

6.50801E-07

1.68911E-06

3.05284E-07

5.93199E-07

max

1.47979E-05

2.55146E-05

2.01758E-05

4.3055E-05

9.30115E-06

9.27677E-06

24
TABLE 15 - FINGER NICOTINE FREQUENCY BAND DATA

SUBJECT

FINGER
NICOTINE
LOW FREQ
BAND PRE

FINGER
NICOTINE
LOW FREQ
BAND
POST

FINGER
NICOTINE
INTERMEDIATE
FREQ BAND
PRE

FINGER
NICOTINE
INTERMEDIATE
FREQ BAND
POST

FINGER
NICOTINE
HIGH
FREQ
BAND PRE

1
2
3
4
5
6
7
8
9
10

9.75286E-06
4.94911E-05
0.000107402
0.0413554
7.3962E-06
6.17572E-05
5.58782E-06
0.001285944
0.000277408
1.48032E-05

0.000109955
3.74795E-05
0.000167871
7.52615E-06
7.52765E-06
0.000761967
3.52351E-06
0.001096446
0.002191646
0.000142084

2.05979E-06
3.16592E-06
1.56064E-05
0.017088506
1.0757E-06
6.16374E-05
3.79876E-05
0.000105332
3.86844E-05
9.32949E-06

2.9737E-05
1.9876E-05
2.29289E-05
8.77705E-06
1.77838E-06
9.37107E-05
3.11302E-05
0.000285643
0.000415072
1.20237E-05

5.27039E-06
2.95105E-06
4.69651E-06
0.005713136
9.84427E-07
5.08541E-06
2.14153E-06
2.63514E-05
1.45515E-05
1.00419E-06

FINGER
NICOTINE
HIGH
FREQ
BAND
POST
1.7429E-05
1.9453E-05
4.7293E-06
1.5021E-06
1.6627E-06
1.3548E-05
1.9917E-06
6.0851E-05
0.00012599
4.2494E-06

MEAN
SD
median
min
max

0.004317494
0.013019687
5.56242E-05
5.58782E-06
0.0413554

0.000452603
0.000714889
0.000126019
3.52351E-06
0.002191646

0.001736338
0.005394303
2.6797E-05
1.0757E-06
0.017088506

9.20676E-05
0.000141771
2.63329E-05
1.77838E-06
0.000415072

0.000577617
0.001804455
4.89096E-06
9.84427E-07
0.005713136

2.5141E-05
3.9681E-05
9.1388E-06
1.5021E-06
0.00012599
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TABLE 16- FINGER NITRO FREQUENCY BANDS

SUBJECT

FINGER
NITRO LOW
FREQ
BAND PRE

FINGER
NITRO LOW
FREQ BAND
POST

FINGER NITRO
INTERMEDIATE
FREQ BAND
PRE

FINGER NITRO
INTERMEDIATE
FREQ BAND
POST

FINGER
NITRO HIGH
FREQ BAND
PRE

1
2
3
4
5
6
7
8
9
10

1.75291E-05
3.19867E-05
4.01445E-05
1.7061E-05
0.000317087
0.006798816
0.004471654
0.001604435
0.01005842
0.000269287

0.000107778
0.000327441
0.000159734
0.000329429
0.00281988
0.008085137
0.012267326
0.00154584
0.002191646
0.014502756

0.000107778
4.81822E-06
5.03476E-06
6.49765E-06
1.15429E-05
0.000298998
0.000591854
0.000140052
0.001690569
0.000178567

1.15721E-05
6.68372E-05
4.23115E-05
0.000208551
0.000515224
0.000246301
0.001551734
0.000195113
0.000788539
0.000784759

1.8499E-05
2.55548E-06
1.5365E-05
1.59516E-05
1.83789E-05
0.000135497
0.000351921
4.68507E-05
0.000274101
6.69528E-05

FINGER
NITRO
HIGH
FREQ
BAND
POST
7.12234E-06
1.02487E-05
2.76726E-05
4.3457E-05
5.17014E-05
4.99673E-05
0.000123079
3.18929E-05
0.000195189
0.00014961

MEAN
SD
median
min
max

0.002362642
0.003564035
0.000293187
1.7061E-05
0.01005842

0.004233697
0.005398995
0.001868743
0.000107778
0.014502756

0.000303571
0.00052063
0.000123915
4.81822E-06
0.001690569

0.000441094
0.000484648
0.000227426
1.15721E-05
0.001551734

9.46073E-05
0.000122786
3.26748E-05
2.55548E-06
0.000351921

6.89939E-05
6.41399E-05
4.67122E-05
7.12234E-06
0.000195189

The vasodilation associated with each drug was accompanied by increases in each
frequency band.
Nonparametric Kruskal-Wallis one-way anova was used to test the difference in
following variables among three frequency groups (low, intermediate, high). Unadjusted
p-values were shown.
Results:
Pre Forehead Nicotine, p= 0.18; Post Forehead Nicotine, p = 0.054
Pre Forehead Nitroglycerin, p = 0.25; Post Forehead Nitroglycerin, p = 0.23
Pre Finger Nicotine, p = 0.23; Post Finger Nicotine, p = 0.04
Pre Finger Nitroglycerin, p = 0.42; Post Finger Nitroglycerin, p = 0.003
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The results show no statistical significance for pre measurements among three frequency
groups. For post- measurements, there was significant difference in post Finger nitro
among three groups (p = 0.003). There was nominal difference in Post finger nicotine (p
= 0.04), which however became non-significant at all if we apply multiple test
adjustments.
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DISCUSSION

Both transdermal nicotine and nitroglycerin resulted in vasodilation of the
forehead microvasculature resulting in a statistically significant increase in blood flow as
measured by the laser Doppler. Nicotine resulted in a larger increase in baseline blood
flow than nitroglycerin (285% (0.07 0.27) vs 122% (0.081  0.18)). It also resulted in
a larger increase in height for nicotine 200% (0.03 0.09) vs nitroglycerin 104% (0.024 
0.049). It is not clear whether this effect is dose dependent. In addition, both drugs caused

a significant increase in the baseline and height of the waveform when compared with
placebo.

Nicotine produced a greater increase in both baseline and height of the

waveform compared with nitroglycerin.
The vasodilation due to the transdermal nicotine can be explained by nicotine
stimulating cholinergic activity. While the forehead microvasculature receives dual
innervation from the parasympathetic and sympathetic nervous systems, transdermal
nicotine only was able to act upon the ganglionic junctions of the parasympathetic system
since these synapse near the end organ( i.e the blood vessels). Since nicotine was not
able to access the synapses of the sympathetic system located in the thoracolumbar chain
it did not stimulate the sympathetic nervous system to produce vasoconstriction. Nicotine
was associated with increased oscillatory activity at every frequency band.
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It is possible, but very unlikely that nicotine was able to gain access to the
nicotinic receptors of the sympathetic system given the low doses used and the short time
frame < 30 minutes in which to act. It is more likely that feedback mechanisms in place
to regulate blood flow were activated resulting in the sympathetic system
counterbalancing the direct activation of the parasympathetic system.
At the finger, there is no appreciable parasympathetic innervation and hence there
was no satistically significant vasodilation associated with transdermal nicotine at the
finger.
Nitroglycerin is a known vasodilator which works via a different mechanism from
nicotine.

It is able to produce vasodilation without activating the parasympathetic

nervous system. In 1977 Murad discovered that nitric oxide release caused by nitrates
relaxes smooth muscle cells. In addition, in 1986 Ignarro proposed that endothelium
derived relaxing factor (EDRF) is identical to NO.

These Nobel prize winners

established the involvement of endothelium in the coordination of numerous vasoactive
factors that play an important role in the regulation of blood vessels.
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ANALYSIS OF RHYTHMIC SIGNALS OF THE AUTONOMIC NERVOUS
SYSTEM

In other to maintain the delicate homeostasis required for sustaining life, the body
must be able to respond appropriately to both external and internal stimuli. These
responses are carried out by the autonomic nervous system through dynamic interactions
of rhythmically discharging neuronal networks. This physiological control system
consists of both the sympathetic and parasympathetic branches which are each
characterized by rhythmic activity. These biologic rhythms include slow and fast
components and the cycle times can be measured and characterized using various
mathematical manipulations to extract the wealth of information hidden within. Each
branch of the autonomic nervous system oscillates within a specific range. The existence
of a rhythm in the autonomic nervous system is important in that it allows the
coordination of the numerous components of the system and it also gives us the ability to
predict future events. Moreover, each component oscillates at a particular frequency and
hence this allows characterization of the response.
Sympathetic activity is associated with the low frequency range 0.05- 0.11 Hz
while parasympathetic activity is associated with intermediate range (0.11-0.19 Hz) and
high range (0.2-0.3Hz) oscillations, with the later associated with respiration. Hence, a
number of different analytical methods were employed for this analysis. This involved
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analyzing the data in both the time and frequency domains as we looked for changes in
amplitude and frequency as well as measuring the changes in mean blood flow.
Chartview, the software used to acquire the data has built in functions for this analysis.
Hence spectral analysis allows us to determine whether the response was predominantly
parasympathetic or sympathetic. This involved converting the data from the time domain
into a frequency domain which allowed us to measure the magnitude of the change in
power at a given frequency.
It is very common for information to be encoded in the sinusoids that form a
signal. This is true of naturally occurring signals, as well as those that have been created
by humans. Many things oscillate in our universe. The shape of the time domain
waveform is not important in these signals; the key information is in the frequency, phase
and amplitude of the component sinusoids. A fourier transform can be utilized to extract
these data allowing us to look more closely at the frequencies. Hence spectral analysis
allows us to determine whether the response was predominantly parasympathetic or
sympathetic.
In our case this was used to study the amplitude, frequency and the power of the
signals. It is clear that there is oscillatory activity in the forehead nicotine with an
increase in amplitude
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ORGANIZATION OF ANS: REGIONAL DIFFERENCES IN INNERVATION

The differences in responses to transdermal nicotine and nitroglycerin support the
hypothesis that there are differences in the innervations to the finger and the forehead.
Moreover, the different degrees of vasodilation in response to nitroglycerin in the
forehead and finger suggest that the differences also exist in the vasculature itself. The
forehead produced a much larger increase in blood flow compared with the finger for
both nicotine and nitroglycerin.
Given the mechanism of action of nicotine, it is not surprising that transdermal
nicotine failed to produce a significant change in blood flow as detected by laser doppler
when applied to the finger. This is due to the fact that the autonomic innervation of the
vasculature in the limb skeletal muscles is primarily sympathetic. In addition, this is
mostly vasoconstrictive and noradrenergic.

As mentioned earlier, nicotine binds to

nicotinic receptors at the pre-to post ganglionic junctions. In the case of the sympathetic
system to the upper limb, these synapses are found in the middle to caudal thoracic spinal
segments and possibly from the lower part of the cervical portion of the sympathetic
ganglionic cord. Hence, the low dose of transdermal nicotine applied in this study was
unable to access them and activate the sympathetic response. Despite this theory,
Nicotine was associated with an increase in blood flow in 2/10 subjects which may
suggest that there may be some receptors in the smooth muscle that nicotine can activate.
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It is well known that there is no parasympathetic innervation to the upper and
lower extremities. The primary role of the parasympathetic nervous system is internal
maintenance, digestion and excretion. Therefore, there were no parasympathetic synapses
near the end organ (i.e microvasculature) as was the case in the forehead for the
transdermal nicotine to activate.
The forehead microvasculature is richly innervated by both sympathetic and
parasympathetic fibers. These include the cranial parasympathetic, superior cervical
sympathetic and the trigeminal sensory nerves.

33

NICOTINE AS A MEANS TO ASSESS THE MICROVASCULAR FUNCTION

The role of transdermal nicotine patches in smoking cessation is well established
and hence these patches are already widely used for that purpose. However, as elucidated
in this study, transdermal nicotine patches may well be an ideal tool for testing and
assessing the function of the microvasculature. In order for transdermal nicotine to
produce a vasodilatory response, the parasympathetic fibers innervating the
microvasculature must be intact. Hence transdermal nicotine assesses both the
innervation ( i.e the post ganglionic pathway) as well as the vessel itself. Many diseases
affect the microvasculature such as diabetes, hypertension and preeclampsia.
This test would be valuable in assessing diabetic neuropathy. Current diabetic
clinical guidelines recommend annual screening for neuropathy but the literature is
unable to provide specific support for a particular screening test due to a lack of evidence
for its validity in the medical literature. In fact, the optimal method for screening for
neuropathy has been controversial and is based on expert opinion rather than clinical
evidence. [8] The development of diabetic neuropathy is an insidious and progressive
process which is not well correlated to the development of symptoms. Diabetic
neuropathy leads to significant morbidity and mortality as it leads to painful paresthesias,
sensory ataxia, ulceration and amputation. Screening and early identification allows an
early opportunity to intervene by improving glycemic control and initiating measures
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such as early foot care before the effects start to unfold. The current screening modalities
in use include mainly the Semmes-Weinstein 5.07/10g monofilament, vibration testing
with a 128 Hz tuning fork and superficial pain sensation testing. [8]
The main advantage of using laser Doppler flowmetry in conjunction with
transdermal nicotine patch is that it would be non invasive, able to detect dysfunction at
an earlier stage, would be user independent and patient independent in the sense that the
patient will not have to subjectively qualify the decreases in sensation. Like any other
quantifiable measurement such as blood pressure, we would be able to better stratify risks
through studies and make recommendations based on those values with the clinical
picture in mind. Clinical trial evidence for the efficacy of screening strategies
demonstrated reduced outcomes of amputation and ulceration and, consequently,
screeningfor neuropathy is recommended in clinical practice guidelines [8].
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NITROGLYCERIN AS A MEANS TO ASSESS THE ENDOTHELIUM

The endothelial cells release a wide number of molecules that regulate
homeostasis, vasomotor activity, hemostasis and inflammation. Nitric oxide is one of
these molecules and has numerous effects. Nitric oxide has vasodilatory, antiinflammatory, antithrombotic effects, antioxidant, antiapoptotic and antithrombotic
effects.

Hence endothelial dysfunction has the potential to affect many different

regulation pathways. Endothelial dysfunction is important in a number of disease states.
This dysfunction leads to a pro-inflammatory and pro-thrombotic state that is thought to
play a major role in the development of atherosclerosis and its accompanying clinical
complications. Moreover, it is also thought to be a predictor of an increased rate of
adverse cardiovascular events.
The endothelium is often evaluated in terms of its vasodilatory function. Several
methods are available for assessing endothelial function by measuring endothelial
dependent vasodilation. Vasodilation can be induced by the direct infusion of a
vasodilator such as acetylcholine or non invasively by the increase in blood flow velocity
caused by post occlusive hyperemia. Using a transdermal patch with a Laser Doppler
probe provides a quick, non invasive way of assessing the endothelial function which is
also quantifiable.

It is clear that nitroglycerin produced in measurable response

compared to placebo and the forehead and finger.
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